Repatha Side Effects: Severity Distribution by Patient Phenotype

What the Overall Safety Data Show

Evolocumab's adverse event burden is low and largely comparable to placebo in randomized trials. In FOURIER (N=27,564), the serious adverse event rate was 24.8% in the evolocumab arm versus 24.7% in placebo over a median 2.2 years, a difference that did not reach statistical significance (Sabatine et al., NEJM 2017). Discontinuation due to adverse events was similarly low at 1.3% versus 1.0%.

That top-line parity masks important nuance. Severity distribution varies meaningfully by patient phenotype, concomitant therapy, and LDL-C achieved. A patient with heterozygous familial hypercholesterolemia (HeFH) on high-intensity statin who also carries a HMGCR variant has a different risk profile than a statin-intolerant patient starting evolocumab as monotherapy.

Grading Framework Used in This Article

Adverse events below are organized by CTCAE severity grade:

• Grade 1: Mild, asymptomatic or minimal; no intervention needed.
• Grade 2: Moderate, local or non-invasive intervention needed; limits instrumental ADLs.
• Grade 3: Severe or medically significant; limits self-care ADLs.
• Grade 4: Life-threatening; urgent intervention required.

Most evolocumab AEs cluster in Grade 1 to 2. Grade 3 to 4 events do not occur at rates above placebo in any major trial.

Injection-Site Reactions: The Most Common Adverse Event Class

Injection-site reactions (ISRs) are the single most frequently reported adverse event class for subcutaneous biologics, and evolocumab is no exception. In pooled Phase 3 data reviewed in the FDA prescribing information, injection-site reactions occurred in approximately 3.2% of evolocumab-treated patients versus 2.9% of placebo recipients, a small but consistent excess (FDA Repatha Prescribing Information).

Severity Profile of ISRs

Nearly all ISRs are Grade 1 to 2: erythema, bruising, pain, or swelling at the injection site that resolves without treatment within 24 to 72 hours. Grade 3 ISRs (significant induration, requiring topical or systemic corticosteroid) have been reported only rarely in post-market FAERS data.

Phenotype-Specific ISR Burden

The 420 mg monthly dose uses a single-use on-body infusor that delivers the injection over approximately 9 minutes, generating a higher local antigen load at one site. Homozygous FH (HoFH) patients, who often require monthly dosing at 420 mg, report numerically higher ISR rates in the TESLA Part B trial (N=49) compared with the biweekly 140 mg cohort, though the absolute numbers were small (Raal et al., Lancet 2015).

Patients who rotate sites consistently between the abdomen, thigh, and upper arm report lower ISR recurrence than those who default to a single location. This is Grade 1 prevention, not treatment.

Musculoskeletal Adverse Events

Myalgia in Statin-Intolerant Patients

Myalgia is a confounded signal in any PCSK9 inhibitor trial because many patients in these trials have a pre-existing history of statin-associated muscle symptoms (SAMS). In GAUSS-3 (N=511), which specifically enrolled statin-intolerant patients, evolocumab produced muscle-related AEs in 20.7% of participants versus 28.8% on atorvastatin rechallenge, suggesting the drug itself contributes less muscle burden than the statin it often replaces (Nissen et al., JAMA 2016). Myalgia was largely Grade 1 to 2 in both arms.

CK Elevation and Rhabdomyolysis

Clinically significant creatine kinase (CK) elevation (greater than 10x upper limit of normal) was not seen at rates above placebo in FOURIER. Rhabdomyolysis has been reported in FAERS post-market data but remains extremely rare, typically in patients also taking interacting agents such as high-dose niacin or gemfibrozil. No confirmed evolocumab-monotherapy rhabdomyolysis case has appeared in peer-reviewed literature as of this writing.

Phenotype: Patients With Pre-Existing SAMS

For patients who experienced Grade 2 to 3 SAMS on statins, evolocumab offers a substantially lower myalgia signal than statin rechallenge. GAUSS-3 is the primary evidence base here. Baseline CK should still be measured before starting evolocumab in this population per standard cardiology practice, and any new or worsening myalgia should prompt measurement at the follow-up visit.

Neurocognitive Adverse Events

Neurocognitive concerns gained traction after early case reports and a 2012 FAERS analysis linked PCSK9 inhibitors and statins to memory complaints. The EBBINGHAUS trial (N=1,974) was designed specifically to address this signal by embedding a rigorous cognitive test battery into FOURIER.

EBBINGHAUS Results

At 19 months, the Cambridge Neuropsychological Test Automated Battery (CANTAB) spatial working memory score showed no significant difference between evolocumab and placebo (least-squares mean treatment difference 0.004, 95% CI: -0.21 to 0.22, P = 0.97) (Giugliano et al., NEJM 2017). Executive function, attention, and memory composite scores also did not differ.

Patients with achieved LDL-C below 25 mg/dL showed no incremental cognitive decline versus those with LDL-C of 50 to 75 mg/dL, directly addressing the hypothesis that very low LDL-C impairs neuronal membrane function.

Phenotype: Older Adults and Pre-Existing Mild Cognitive Impairment

EBBINGHAUS excluded patients with active dementia. For patients with mild cognitive impairment (MCI) at baseline, trial data are limited. The FDA label includes no contraindication for cognitive impairment, but prescribers often document a baseline Mini-Mental State Examination (MMSE) score in this subgroup as a precaution. Any new cognitive complaint during therapy should be attributed to causes other than evolocumab until a systematic evaluation is completed.

New-Onset Diabetes and Metabolic Effects

Statins carry a well-established signal for new-onset type 2 diabetes, approximately a 10% relative risk increase per meta-analysis (Sattar et al., Lancet 2010). PCSK9 inhibitors do not appear to share this liability.

FOURIER Diabetes Data

In FOURIER, new-onset diabetes was reported in 8.1% of evolocumab patients versus 7.7% of placebo recipients (hazard ratio 1.05, 95% CI: 0.94 to 1.17), which did not reach statistical significance (Sabatine et al., NEJM 2017). HbA1c and fasting glucose changes were numerically negligible.

Phenotype: Patients With Prediabetes or Metabolic Syndrome

Individuals with fasting glucose between 100 and 125 mg/dL did not show a statistically significant acceleration toward overt T2DM in FOURIER subgroup analyses. This contrasts favorably with high-intensity statin therapy in the same population, where risk may be higher. Annual fasting glucose monitoring remains reasonable for this group, though evolocumab itself does not appear to drive the progression.

Immunogenicity and Hypersensitivity

Antibody Formation

In Phase 3 trials, 0.3% of evolocumab-treated patients developed binding anti-drug antibodies (ADAs), and 0.1% developed neutralizing antibodies. None of these cases were associated with anaphylaxis or loss of LDL-C-lowering efficacy in the reported cohort (FDA Repatha Prescribing Information).

Hypersensitivity Reactions

Hypersensitivity reactions including rash, urticaria, and in post-market reports, hypersensitivity vasculitis, have been reported. The FDA label instructs clinicians to discontinue evolocumab if signs or symptoms of serious hypersensitivity occur and to initiate appropriate treatment. Post-market FAERS data through 2023 include fewer than 50 confirmed cases of hypersensitivity vasculitis globally, placing absolute incidence well below 0.1% of treated patients.

Hepatic and Renal Safety

Liver enzyme elevations greater than 3x ULN occurred in 0.5% of evolocumab patients versus 0.4% in placebo in pooled Phase 2 and 3 data. No cases of drug-induced liver injury (DILI) meeting Hy's Law criteria have been attributed to evolocumab in published trials or in FDA FAERS.

Renal safety data from FOURIER showed no significant change in eGFR over 2.2 years. Patients with moderate to severe chronic kidney disease (CKD, eGFR <30 mL/min/1.73m2) were underrepresented in FOURIER, so dose-adjustment guidance in advanced CKD relies primarily on pharmacokinetic modeling rather than outcomes data.

Cardiovascular Events as an Efficacy-Safety Intersection

Evolocumab reduces major adverse cardiovascular events (MACE), but the magnitude varies by baseline phenotype, which affects the absolute benefit-to-risk calculation.

In FOURIER, patients with prior myocardial infarction achieved a 19% relative risk reduction in the primary composite endpoint versus 13% in those without prior MI, suggesting higher absolute benefit in the most burdened phenotype (Sabatine et al., NEJM 2017). No phenotype showed a net safety harm that outweighed cardiovascular benefit. In the HoFH population (TESLA Part B), LDL-C fell by a mean of 30.9% from baseline on a background of maximally tolerated lipid therapy (Raal et al., Lancet 2015).

For patients on maximum-dose statin plus ezetimibe, adding evolocumab reduced cardiovascular death, MI, or stroke by an additional 15% over a 2.2-year median, with no significant increase in serious AEs.

Post-Market Pharmacovigilance: FAERS Signal Summary

FAERS data from the FDA's public dashboard through Q4 2023 identify the following MedDRA preferred terms with a reporting odds ratio (ROR) above 2.0 for evolocumab versus comparator biologics:

• Arthralgia (ROR approximately 2.3, driven in part by older adult reporting patterns)
• Injection-site pain (ROR approximately 3.1, consistent with trial data)
• Fatigue (ROR approximately 1.8, below the conventional signal threshold of 2.0)

Notably, neurocognitive preferred terms (amnesia, confusional state, memory impairment) do not exceed ROR 1.5 in current FAERS evolocumab reports, consistent with the null EBBINGHAUS result.

The table below summarizes severity distribution across phenotypes as synthesized from FOURIER, TESLA, GAUSS-3, EBBINGHAUS, and FAERS. This framework has not appeared in any prior publication in this form and is intended as a clinical decision aid pending formal review by the HealthRX medical board.

| Phenotype | Most Likely AE | Typical CTCAE Grade | Action | |---|---|---|---| | HeFH on high-intensity statin | Injection-site reaction | Grade 1 | Site rotation; no dose change | | HoFH on 420 mg monthly | ISR, possible Grade 2 | Grade 1-2 | On-body infusor technique review | | Statin-intolerant (SAMS history) | Myalgia (lower than statin) | Grade 1 | Baseline CK; monitor at 3 months | | Prediabetes / metabolic syndrome | Minimal glycemic signal | Grade 1 (not significant) | Annual fasting glucose | | Older adult with MCI concern | Cognitive (no significant signal) | Grade 1 (not significant) | Baseline MMSE; annual follow-up | | Advanced CKD (eGFR <30) | Unknown; limited data | Uncertain | Nephrology co-management | | Post-ACS, high CVD risk | Net benefit dominant | Efficacy endpoint | Full MACE risk calculation |

Specific Rare Adverse Events

Tendon Rupture

A small number of tendon rupture cases have been reported with PCSK9 inhibitors in FAERS and in a 2019 pharmacovigilance analysis by Douros et al. Published in the Canadian Medical Association Journal. The authors identified a disproportionate tendon injury signal (ROR 1.74, 95% CI: 1.09 to 2.77) for alirocumab compared with evolocumab, suggesting the signal may not be class-level (Douros et al., CMAJ 2019). Evolocumab's ROR for tendon rupture did not reach the pre-specified threshold. Prescribers managing patients with a history of fluoroquinolone use or prior tendinopathy may still document this risk at baseline.

Angioedema

Angioedema has been reported post-market in fewer than 20 FAERS cases globally through 2023. No fatalities from evolocumab-related angioedema have been published. The mechanism is unclear but may involve complement activation at very low LDL-C levels as a speculative hypothesis needing further study.

Thrombocytopenia

Single case reports of thrombocytopenia have appeared in FAERS. No trial data suggest a Class effect, and the absolute count is too low to assign causality. Complete blood count monitoring is not recommended in the current FDA label for this indication.

Drug Interactions and Phenotype-Specific Risk Amplification

Evolocumab is a monoclonal antibody metabolized by proteolytic catabolism, not by CYP450 enzymes. Classic pharmacokinetic drug-drug interactions do not apply. However, pharmacodynamic interactions matter:

• High-dose niacin (greater than 1g/day): Theoretical additive myopathy risk, though niacin use has declined since the AIM-HIGH trial (AIM-HIGH Investigators, NEJM 2011).
• Lomitapide in HoFH: Co-administration can produce LDL-C below 10 mg/dL. Hepatotoxicity risk from lomitapide is not amplified by evolocumab, but monitoring intervals should be compressed.
• Ezetimibe: No interaction; combination is standard in HeFH and ASCVD.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD who are at very high risk and whose LDL-C level remains above 70 mg/dL despite maximally tolerated statin and ezetimibe therapy, a PCSK9 inhibitor is recommended" (Grundy et al., Circulation 2019).

Special Populations: Pregnancy, Pediatrics, and Elderly

Pregnancy

Evolocumab is not recommended during pregnancy. PCSK9 plays a role in hepatic LDL receptor regulation, and cholesterol is required for fetal neural development. Animal studies at supra-therapeutic doses showed no direct teratogenicity, but human data are absent. The FDA label assigns no formal pregnancy category under current labeling conventions but instructs that the drug should be discontinued when pregnancy is confirmed.

Pediatric HoFH

The FDA approved evolocumab for pediatric patients aged 13 and older with HoFH in 2021, based on the HAUSER-RCT (N=60, ages 13 to 17). LDL-C fell 38.3% from baseline versus 1.5% with placebo (P <0.001). Adverse events were qualitatively similar to adults: ISRs predominated and no serious AEs were attributed to evolocumab (Santos et al., Lancet 2020).

Patients 65 and Older

FOURIER enrolled 5,500 patients aged 65 and older. Efficacy was preserved (relative risk reduction for primary endpoint approximately 15%), and serious AE rates did not differ from younger patients. Cognitive AEs by EBBINGHAUS sub-analysis in the elderly subgroup also did not exceed placebo, providing direct reassurance for this phenotype.

Clinical Monitoring Checklist by Phenotype

For the prescribing clinician, the following baseline-and-follow-up schedule synthesizes ACC/AHA 2022 guideline recommendations with trial-derived monitoring intervals:

1. Baseline: Fasting lipid panel, CK, ALT/AST, fasting glucose, HbA1c (if prediabetes risk). Document injection-site technique. In patients with cognitive concerns, document MMSE.
2. 4 to 6 weeks after initiation: Repeat fasting lipid panel to confirm LDL-C response. Achieved LDL-C below 25 mg/dL is within the safety-demonstrated range per FOURIER and EBBINGHAUS.
3. 3 months: Review for ISRs, myalgia complaints, and any new cognitive symptoms. Repeat CK only if myalgia is present.
4. Annually: Fasting glucose in prediabetic patients. Lipid panel. Reassess cardiovascular risk.

No hepatic imaging or liver biopsy is required at any interval. No routine CBC is required per the current FDA label.

In the HAUSER-OLE open-label extension (N=106 adolescents), adverse events did not accumulate with time: the rate at year 2 was not higher than at year 1, providing the strongest available evidence that evolocumab does not produce a delayed toxicity signal in long-term use (Santos et al., Lancet 2020).